CAR-T Platform Process
UPTEMPO℠ CAR-T CELL THERAPY PLATFORM, A FULLY CLOSED GMP COMPLIANT CAR-T CELL WORKFLOW THAT CAN FAST-TRACK YOUR PATH TO PATIENT
When there is no time to waste, we offer speed without compromise. Fast-track your path to patient with Catalent’s UpTempo℠ CAR-T Cell Therapy Platform:
- Fully closed workflow: aseptic, automated connection between devices
- Data-driven guidance to build a seamless, robust, modular platform
- State-of-the-art technologies
- Minimal hands-on operator time
- Optionality and customizability: add your own device to the plug and play platform
- Proof of concept data that can be leveraged for faster process development
- Quality by design approach: Process optimization with design of experiments
- CMC and regulatory support
- Reduced risk without compromising quality
- Suitable for autologous and allogeneic
Catalent’s data-driven guidance can help innovators leverage deep process knowledge to optimize each step of the workflow from sample collection, cell activation, transduction, expansion, fill and finish and formulation of final drug product, providing a robust, automated, aseptic process, supported by Catalent’s regulatory and analytical teams.
A solid foundation is the key to success. Catalent can support your journey from critical raw materials to commercial supply through a flexible and transparent partnership. Catalent offers the following as a full-service CDMO partner for cell therapy:
- Hands on experience in development and execution of cell therapies
- Global facilities and on-site capabilities
- Plasmid and viral vector capabilities
- Expertise across a variety of cell types including chimeric antigen receptor T cells (CAR-T), T cell receptors (TCR), tumor-infiltrating leukocytes (TILs), natural killer cells (NKs), iPSCs, and MSCs
- Process and analytical development to clinical and commercial manufacturing
- Vein to vein support with Catalent’s Case Management Services